- Home
- ENGN vs RCEL Comparison
ENGN vs RCEL Comparison
Compare ENGN & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- RCEL
- Stock Information
- Founded
- ENGN 1999
- RCEL 2020
- Country
- ENGN Canada
- RCEL United States
- Employees
- ENGN N/A
- RCEL N/A
- Industry
- ENGN
- RCEL Medical/Dental Instruments
- Sector
- ENGN
- RCEL Health Care
- Exchange
- ENGN Nasdaq
- RCEL Nasdaq
- Market Cap
- ENGN 317.6M
- RCEL 308.6M
- IPO Year
- ENGN N/A
- RCEL N/A
- Fundamental
- Price
- ENGN $7.06
- RCEL $12.79
- Analyst Decision
- ENGN Strong Buy
- RCEL Buy
- Analyst Count
- ENGN 9
- RCEL 4
- Target Price
- ENGN $29.78
- RCEL $19.33
- AVG Volume (30 Days)
- ENGN 162.9K
- RCEL 117.4K
- Earning Date
- ENGN 12-19-2024
- RCEL 02-20-2025
- Dividend Yield
- ENGN N/A
- RCEL N/A
- EPS Growth
- ENGN N/A
- RCEL N/A
- EPS
- ENGN N/A
- RCEL N/A
- Revenue
- ENGN N/A
- RCEL $60,040,000.00
- Revenue This Year
- ENGN N/A
- RCEL $40.34
- Revenue Next Year
- ENGN N/A
- RCEL $52.79
- P/E Ratio
- ENGN N/A
- RCEL N/A
- Revenue Growth
- ENGN N/A
- RCEL 32.24
- 52 Week Low
- ENGN $4.42
- RCEL $7.51
- 52 Week High
- ENGN $18.40
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- ENGN 50.68
- RCEL 52.40
- Support Level
- ENGN $6.08
- RCEL $12.64
- Resistance Level
- ENGN $6.54
- RCEL $13.95
- Average True Range (ATR)
- ENGN 0.82
- RCEL 0.72
- MACD
- ENGN 0.09
- RCEL 0.02
- Stochastic Oscillator
- ENGN 61.60
- RCEL 56.23
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.